FLOT1 and metastatic prostate carcinoma: However, no significant difference of FLOT1 (Flot-1) expression was detected among benign and primary and metastatic prostate cancer tissues, whereas UBE2I (UBC9) expression was significantly higher in metastatic prostate cancer tissues than in benign and primary prostate cancer tissues (Fig. 6d).